Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methadone rotation for refractory cancer-induced bone pain
ACTRN12621000141842Phase 2Not yet recruiting
- Sponsor
- Dr Merlina Sulistio
- Start
- Feb 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methadone, morphine, oxycodone and hydromorphone in refractory cancer-induced bone pain (2 arms), sponsored by Dr Merlina Sulistio. Primary endpoints: Change in worst pain intensity at Day 14 and Change in average pain intensity at Day 14. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
methadonemorphineoxycodonehydromorphone
03
Conditions
refractory cancer-induced bone pain
Beyond the preview
Go deeper on ACTRN12621000141842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000141842.